Navigation Links
Watson to Present at CLSA/Asia USA Investor's Forum
Date:2/26/2010

MORRISTOWN, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview of the Company's business at the CLSA/Asia Investor's Forum on Tuesday, March 2, 2010 at 4:30 pm Eastern Standard Time at the Westin St. Francis in San Francisco, CA.

This presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  

The webcast can also be accessed at the following URL:

http://www.clsa.com/forum/sf10/index.cfm?display=live-streaming&id=10040 

An archived version will be available for 60 days after the live presentation and can be accessed at the same locations.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on urology, women's health. Watson has operations in many of the world's established and growing international markets.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

SOURCE Watson Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.watson.com

'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide ... we as a society can control and change. , As nearly 795,000 Americans suffering ... seconds within the United States. Plus, with an estimated 129,000 of these people dying ...
Breaking Medicine News(10 mins):